The role of irreversible HER family inhibition in the treatment of patients with non-small cell lung cancer

Oncologist

Volumn 16, Issue 11, 2011, Pages 1498-1507

  Kwak, Eunice ^a  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

Afatinib (BIBW 2992); Irreversible EGFR HER 2 tyrosine kinase inhibitors; Non small cell lung cancer; PF00299804; Resistance

Indexed keywords

4 ANILINOQUINAZOLINE; AFATINIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DACOMITINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; NERATINIB; PACLITAXEL; PEMETREXED; PLACEBO; RAPAMYCIN; SIMVASTATIN; TEMSIROLIMUS; UNCLASSIFIED DRUG; WZ 4002;

ADVANCED CANCER; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL EVALUATION; DEHYDRATION; DIARRHEA; DRUG APPROVAL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG RESISTANCE; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DYSPNEA; ENZYME INHIBITION; ERYTHEMA; FATIGUE; GENE DOSAGE; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SINGLE DRUG DOSE; SKIN MANIFESTATION; STOMATITIS; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME;

CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, ERBB-2;

EID: 82355190618     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0087     Document Type: Article

References (88)

1. Roskoski R Jr. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun 2004;319:1-11.
2. Sibilia M, Kroismayr R, Lichtenberger BM et al. The epidermal growth factor receptor: From development to tumorigenesis. Differentiation 2007; 75:770-787.
3. Britten CD. Targeting ErbB receptor signaling: A pan-ErbB approach to cancer. Mol Cancer Ther 2004;3:1335-1342.
4. Grandis JR, Sok JC. Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther 2004; 102:37-46.
5. Citri A, Skaria KB, Yarden Y. The deaf and the dumb: The biology of ErbB-2 and ErbB-3. Exp Cell Res 2003;284:54-65.
6. Olayioye MA, Neve RM, Lane HA et al. The ErbB signaling network: Receptor heterodimerization in development and cancer. EMBO J 2000;19: 3159-3167.
7. Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: Targets for cancer therapy. Nat Rev Cancer 2004;4:361-370.
8. Hynes NE, Schlange T. Targeting ADAMS and ERBBs in lung cancer. Cancer Cell 2006;10:7-11.
9. Araújo A, Ribeiro R, Azevedo I et al. Genetic polymorphisms of the epidermal growth factor and 1506Irreversible HER Family Inhibition in NSCLC related receptor in non-small cell lung cancer-a review of the literature. The Oncologist 2007;12: 201-210.
10. Joy AA, Butts CA. Extending outcomes: Epidermal growth factor receptor-targeted monoclonal antibodies in non-small-cell lung cancer. Clin Lung Cancer 2009;10(suppl 1):S24-S29.
11. Ganjoo KN, Wakelee H. Review of erlotinib in the treatment of advanced non-small cell lung cancer. Biologics 2007;1:335-346.
12. Fukuoka M, Yano S, Giaccone G et al. Multiinstitutional randomized phase II trial of gefitinib for previously treated patients with advanced nonsmall-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003;21:2237-2246.
13. Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 2003;290:2149-2158.
14. Pérez-Soler R, Chachoua A, Hammond LA et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004;22:3238-3247.
15. Sharma SV, Bell DW, Settleman J et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-181.
16. Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 1. J Clin Oncol 2004;22:777-784.
17. Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 2. J Clin Oncol 2004;22:785-794.
18. Thatcher N, Chang A, Parikh P et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527-1537.
19. AstraZeneca Pharmaceuticals LP. Iressa (gefitinib tablets) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP, 2005.
20. Gatzemeier U, Pluzanska A, Szczesna A et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007;25:1545-1552.
21. Herbst RS, Prager D, Hermann R et al. TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892-5899.
22. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132.
23. Genentech, Inc. Tarceva (erlotinib tablets) [package insert]. South San Francisco, CA: Genentech, Inc., 2010.
24. Genentech Inc. FDA Approves Tarceva as a Maintenance Therapy for Advanced Non-Small Cell Lung Cancer. Available at http://www.gene.com/gene/news/press-releases/displaydo?method=detail&id=12727, accessed April 21, 2010.
25. Roche. Roche Announces Filing of Tarceva in EU as First-Line Maintenance Therapy in Advanced Non-Small Cell Lung Cancer. March 19, 2009. Available at http://www.roche.com/investors/ir_update/inv-update-2009-03-19.htm, accessed May 12, 2010.
26. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350: 2129-2139.
27. Paez JG, Jänne PA, Lee JC et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004;304: 1497-1500.
28. Pao W, Miller V, Zakowski M et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306-13311.
29. Zhang X, Gureasko J, Shen K et al. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 2006;125:1137-1149.
30. Yun CH, Boggon TJ, Li Y et al. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: Mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 2007;11:217-227.
31. Carey KD, Garton AJ, Romero MS et al. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res 2006;66: 8163-8171.
32. Shigematsu H, Lin L, Takahashi T et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-346.
33. Inoue A, Kobayashi K, Usui K et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 2009;27:1394-1400.
34. Porta R, Queralt C, Cardenal F et al. Erlotinib customization based on epidermal growth factor receptor (EGFR) mutations in stage IV non-smallcell lung cancer (NSCLC) patients [abstract 8038]. J Clin Oncol 2008;26(suppl 15):333.
35. Sequist LV, Martins RG, Spigel D et al. Firstline gefitinib in patients with advanced non-smallcell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008;26:2442-2449.
36. Kim ES, Hirsh V, Mok T et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial. Lancet 2008;372:1809-1818.
37. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
38. Astra Zeneca. Iressa (Gefitinib) Receives Marketing Authorisation for the Treatment of NonSmall Cell Lung Cancer in Europe. Available at http://www.astrazeneca.com/Media/Press-releases/Article/20090701-IRESSA-Gefitinib-Receives-Marketing-Authorisation-f, accessed April 8, 2010.
39. Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-128.
40. Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362:2380-2388.
41. Yang CH, Fukuoka M, Mok TS et al. Final overall survival (OS) results from a phase III, randomised, open-label, first-line study of gefitinib (G) V carboplatin/paclitaxel (C/P) in clinically selected patients with advanced non-small cell lung cancer (NSCLC) in Asia (iPASS) [abstract LBA2]. Ann Oncol 2010;21(suppl 8):81-82.
42. Rosell R, Moran T, Queralt C et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-967.
43. Mack PC, Redman MW, Chansky K et al. KRAS and EGFR mutations in the molecular epidemiology of NSCLC: Interim analysis of S0424. J Clin Oncol 2010;28(15 suppl):7013.
44. Bos JL. ras oncogenes in human cancer: A re view. Cancer Res 1989;49:4682-4689.
45. Eberhard DA, Johnson BE, Amler LC et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005;23:5900-5909.
46. Zhu CQ, da Cunha SG, Ding K et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008; 26:4268-4275.
47. Greulich H, Chen TH, Feng W et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med 2005;2:e313.
48. Sequist LV, Waltman B, Dias-Santagata D et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011;3:75-26.
49. Maheswaran S, Sequist LV, Nagrath S et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008;359:366-377.
50. Bell DW, Gore I, Okimoto RA et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet 2005;37:1315-1316.
51. Rosell R, Molina MA, Costa C et al. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced nonsmall-cell lung cancer patients with EGFR mutations. Clin Cancer Res 2011;17:1160-1168.
52. Kobayashi S, Boggon TJ, Dayaram T et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352: 786-792.
53. Kwak EL, Sordella R, Bell DW et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA2005;102:7665-7670.
54. Yun CH, Mengwasser KE, Toms AV et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 2008;105:2070-2075.
55. Engelman JA, Zejnullahu K, Mitsudomi T et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-1043.
56. Engelman JA, Jänne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2008;14:2895-2899.
57. Suda K, Onozato R, Yatabe Y et al. EGFR T790M mutation: A double role in lung cancer cell survival? J Thorac Oncol 2009;4:1-4.
58. Bose P, Ozer H. Neratinib: An oral, irreversible dual EGFR/HER2 inhibitor for breast and nonsmall cell lung cancer. Expert Opin Investig Drugs 2009;18:1735-1751.
59. Rabindran SK, Discafani CM, Rosfjord EC et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res 2004;64:3958-3965.
60. Wong KK, Fracasso PM, Bukowski RM et al. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res 2009;15:2552-2558.
61. Sequist LV, Besse B, Lynch TJ et al. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: Results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol 2010;28:3076-3083.
62. Burstein HJ, Sun Y, Dirix LY et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 2010;28:1301-1307.
63. Janne PA, Boss DS, Camidge DR et al. Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clin Cancer Res 2011;17:1131-1139.
64. Engelman JA, Zejnullahu K, Gale CM et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 2007;67:11924-11932.
65. Janne PA, Schellens JH, Engelman JA et al. Preliminary activity and safety results from a phase I clinical trial of PF-00299804, an irreversible panHER inhibitor, in patients (pts) with NSCLC. J Clin Oncol 2008;26:8027.
66. Janne PA, Reckamp K, Koczywas M et al. A phase 2 trial of PF-00299804 (PF299), an oral irreversible HER tyrosine kinase inhibitor (TKI), in patients (pts) with advanced NSCLC after failure of prior chemotherapy and erlotinib: Preliminary efficacy and safety results [abstract A3.1]. J Thorac Oncol 2009;4(suppl 1):S293-S294.
67. Park K, Heo DS, Cho BC et al. PF299804 in Asian patients with non-small cell lung cancer refractory to chemotherapy and erlotinib or gefitinib: A phase I/II study. Presented at the 46th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 4-8, 2010. www.TheOncologist.com
68. Campbell A, Reckamp KL, Camidge DR et al. PF-00299804 (PF299) patient (pt)-reported outcomes (PROs) and efficacy in adenocarcinoma (adeno) and nonadeno non-small cell lung cancer (NSCLC): A phase (P) II trial in advanced NSCLC after failure of chemotherapy (CT) and erlotinib (E). J Clin Oncol 2010;28(15 suppl):7596.
69. Boyer MJ, Blackhall FH, Park K et al. Efficacy and Safety of PF299804 Versus Erlotinib: A Global, Randomiz
70. Mok T, Spigel DR, Park K et al. Efficacy and safety of PF-00299804 (PF299), an oral, irreversible, pan-human epidermal growth factor receptor (pan-HER) tyrosine kinase inhibitor (TKI), as firstline treatment (tx) of selected patients (pts) with advanced (adv) non-small cell lung cancer (NSCLC). J Clin Oncol 2010;28(15 suppl):7537.
71. Li D, Ambrogio L, Shimamura T et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008;27:4702-4711.
72. Eskens FA, Mom CH, Planting AS et al. A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br J Cancer 2008;98: 80-85.
73. Awada A, Dumez H, Wolter P et al. A phase I dose finding study of the 3-day administration of BIBW 2992, an irreversible dual EGFR/HER2 inhibitor, in combination with 3-weekly docetaxel in patients with advanced solid tumors [abstract 3556]. Presented at the 45th Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 29 to June 2, 2009.
74. Stavridi F, Kristeleit R, Forster M et al. Activity of BIBW 2992, an oral irreversible EGFR/ HER2 dual kinase inhibitor, in combination with weekly paclitaxel in non-small cell lung cancer [abstract PD3.1.5]. J Thorac Oncol 2009;4(suppl 1): S444.
75. Vermorken JB, Machiels JH, Rottey S et al. Phase Ib study evaluating the combination of BIBW 2992 with two different standard chemotherapy regimens, cisplatin/paclitaxel (PT) and cisplatin/5-FU (PF), in patients with advanced solid tumors. J Clin Oncol 2010;28:e13521.
76. Yap TA, Vidal L, Adam J et al. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol 2010;28:3965-3972.
77. Miller VA, Hirsh V, Cadranel J et al. Phase IIB/III double-blind randomized trial of afatinib (BIBW 2992, an irreversible inhibitor of EGFR/ HER1 and HER2) best supportive care (BSC) 1507 versus placeboBSC in patients with NSCLC failing 1-2 lines of chemotherapy and erlotinib or gefitinib (LUX-LUNG 1) [abstract LBA1]. Ann Oncol 2010;21(suppl 8):viii1.
78. Yang C, Shih J, Su W et al. A phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR mutations (LUX-Lung 2). Presented at the 46th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 4 8, 2010.
79. Yang C, Shih J, Su W et al. A phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR/HER1 mutations (LUXLUNG 2) [abstract 367PD]. Ann Oncol 2010; 21(suppl 8):viii123.
80. Jackman DM, Yeap BY, Sequist LV et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 2006; 12:3908-3914.
81. Riely GJ, Pao W, Pham D et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 2006;12:839-844.
82. Ninomiya T, Takigawa N, Kubo T et al. Effect of afatinib on lung cancer burden induced by an exon 19 EGFR mutation in transgenic mice [abstract 3566]. Presented at the 102nd Annual Meeting of the American Association for Cancer Research, Orlando, Florida, April 2-11, 2011.
83. Janne PA, Boss DS, Camidge DR et al. Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clin Cancer Res 2011;17(5):1131-1139.
84. Sos ML, Rode HB, Heynck S et al. Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation. Cancer Res 2010;70:868-874.
85. Gandhi L, Bahleda R, Cleary JM et al. Twodimensional phase I study of neratinib (NER) combined with temsirolimus (TEM) in patients (Pts) with solid tumors. J Clin Oncol 2011;29(suppl): Abstract 3027.
86. Janjigian YY, Groen HJ, Horn L et al. Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib. J Clin Oncol 2011;29(suppl): Abstract 7525.
87. Zhou W, Ercan D, Chen L et al. Novel mutantselective EGFR kinase inhibitors against EGFR T790M. Nature 2009;462:1070-1074.
88. Sharma PS, Sharma R, Tyagi T. Receptor tyrosine kinase inhibitors as potent weapons in war against cancers. Curr Pharm Des 2009;15: 758-776.